Egetis Therapeutics (Sweden) Buy Hold or Sell Recommendation
| EGTX Stock | SEK 5.60 0.04 0.71% |
Assuming the 90 days trading horizon and your above-average risk tolerance, our recommendation regarding Egetis Therapeutics AB is 'Strong Sell'. A buy or sell recommendation provided by Macroaxis is an automated directive regarding whether to purchase or sell Egetis Therapeutics AB given historical horizon and risk tolerance towards Egetis Therapeutics. When Macroaxis issues a 'buy' or 'sell' recommendation for Egetis Therapeutics AB, the advice is generated through an automated system that utilizes algorithms and statistical models.
Check out Egetis Therapeutics Analyst Recommendation to compare Macroaxis Buy or Sell Recommendation with the current analyst consensus. To check ratings for multiple equity instruments, please use the Instant Ratings tool. Note, we conduct extensive research on individual companies such as Egetis and provide practical buy, sell, or hold advice based on investors' constraints. Egetis Therapeutics AB. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in board of governors.
Egetis |
Execute Egetis Therapeutics Buy or Sell Advice
The Egetis recommendation should be used to complement the buy-or-sell advice compiled from the current analysts' consensus on Egetis Therapeutics AB. Macroaxis does not own or have any residual interests in Egetis Therapeutics AB or other equities on which the buy-or-sell advice is provided. Please provide your input below to execute Egetis Therapeutics' advice using the current market data and latest reported fundamentals.
Time Horizon
Risk Tolerance
 |  |
Strong Sell
Market Performance | Very Weak | Details | |
Volatility | Relatively risky | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Quite High | Details | |
Economic Sensitivity | Barely shadows the market | Details | |
Analyst Consensus | Not Available | Details | |
Reporting Quality (M-Score) | Inapplicable | Details |
Egetis Therapeutics Trading Alerts and Improvement Suggestions
| Egetis Therapeutics had very high historical volatility over the last 90 days | |
| Egetis Therapeutics has high likelihood to experience some financial distress in the next 2 years | |
| The company reported the revenue of 38.24 M. Net Loss for the year was (104.54 M) with loss before overhead, payroll, taxes, and interest of (58.28 M). | |
| Egetis Therapeutics AB has accumulated about 207.41 M in cash with (130.11 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.26. | |
| Roughly 52.0% of the company shares are held by company insiders |
Egetis Therapeutics Returns Distribution Density
The distribution of Egetis Therapeutics' historical returns is an attempt to chart the uncertainty of Egetis Therapeutics' future price movements. The chart of the probability distribution of Egetis Therapeutics daily returns describes the distribution of returns around its average expected value. We use Egetis Therapeutics AB price's Value At Risk and its Upside Potential as a relative measure of the distribution. The graph of the distribution of Egetis Therapeutics returns is essential to provide solid investment advice for Egetis Therapeutics.
| Mean Return | 0.02 | Value At Risk | -5 | Potential Upside | 6.76 | Standard Deviation | 4.16 |
Return Density |
| Distribution |
Investment risk management requires an estimate of the probability of extreme price changes. Therefore, the correct representation of the distribution of Egetis Therapeutics historical returns presented in an easy-to-digest graphical form helps investors and money managers understand the risk-reward trade-off of different investement strategies.
Egetis Therapeutics Greeks
Most traded equities are subject to two types of risk - systematic (i.e., market) and unsystematic (i.e., nonmarket or company-specific) risk. Unsystematic risk is the risk that events specific to Egetis Therapeutics or Healthcare sector will adversely affect the stock's price. This type of risk can be diversified away by owning several different stocks in different industries whose stock prices have shown a small correlation to each other. On the other hand, systematic risk is the risk that Egetis Therapeutics' price will be affected by overall stock market movements and cannot be diversified away. So, no matter how many positions you have, you cannot eliminate market risk. However, you can measure a Egetis stock's historical response to market movements and buy it if you are comfortable with its volatility direction. Beta and standard deviation are two commonly used measures to help you make the right decision.
α | Alpha over Dow Jones | -0.0065 | |
β | Beta against Dow Jones | 0.11 | |
σ | Overall volatility | 4.19 | |
Ir | Information ratio | -0.03 |
Egetis Therapeutics Volatility Alert
Egetis Therapeutics AB shows above-average downside volatility for the selected time horizon. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Egetis Therapeutics' stock risk against market volatility during both bullish and bearish trends. The higher level of volatility that comes with bear markets can directly impact Egetis Therapeutics' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different financial instruments as prices fall.Egetis Therapeutics Fundamentals Vs Peers
Comparing Egetis Therapeutics' fundamentals to the average values of its peers is one of the most widely used and accepted methods of equity analyses. It helps to analyze Egetis Therapeutics' direct or indirect competition across all of the common fundamentals between Egetis Therapeutics and the related equities. This way, we can detect undervalued stocks with similar characteristics as Egetis Therapeutics or determine the stocks which would be an excellent addition to an existing portfolio. Peer analysis of Egetis Therapeutics' fundamental indicators could also be used in its relative valuation, which is a method of valuing Egetis Therapeutics by comparing valuation metrics with those of similar companies.
| Better Than Average | Worse Than Average | Compare Egetis Therapeutics to competition |
| Fundamentals | Egetis Therapeutics | Peer Average |
| Return On Equity | -0.26 | -0.31 |
| Return On Asset | -0.14 | -0.14 |
| Operating Margin | (7.54) % | (5.51) % |
| Current Valuation | 698.73 M | 16.62 B |
| Shares Outstanding | 249.59 M | 571.82 M |
| Shares Owned By Insiders | 52.07 % | 10.09 % |
| Shares Owned By Institutions | 14.16 % | 39.21 % |
| Price To Book | 1.52 X | 9.51 X |
| Price To Sales | 42.39 X | 11.42 X |
| Revenue | 38.24 M | 9.43 B |
| Gross Profit | (58.28 M) | 27.38 B |
| EBITDA | (101.9 M) | 3.9 B |
| Net Income | (104.54 M) | 570.98 M |
| Cash And Equivalents | 207.41 M | 2.7 B |
| Cash Per Share | 1.26 X | 5.01 X |
| Total Debt | 4.88 M | 5.32 B |
| Debt To Equity | 0.01 % | 48.70 % |
| Current Ratio | 3.54 X | 2.16 X |
| Book Value Per Share | 2.71 X | 1.93 K |
| Cash Flow From Operations | (130.11 M) | 971.22 M |
| Earnings Per Share | (0.70) X | 3.12 X |
| Target Price | 16.2 | |
| Number Of Employees | 17 | 18.84 K |
| Beta | 1.07 | -0.15 |
| Market Capitalization | 1.51 B | 19.03 B |
| Total Asset | 569.27 M | 29.47 B |
| Net Asset | 569.27 M |
Egetis Therapeutics Market Momentum
Traders often use several daily momentume indicators to supplement a more traditional technical analysis when analyzing securities such as Egetis . With many different options, investors must choose the best indicators for them and familiarize themselves with how they work. We suggest combining traditional momentum indicators with more near-term forms of technical analysis such as Accumulation Distribution or Daily Balance Of Power. With their quantitative nature, daily value technical indicators can also be incorporated into your automated trading systems.
About Egetis Therapeutics Buy or Sell Advice
When is the right time to buy or sell Egetis Therapeutics AB? Buying financial instruments such as Egetis Stock isn't very hard. However, what challenging for most investors is doing it at the right time to beat the market. Proper market timing is something most people cannot do without sophisticated tools, which help to isolate the right opportunities. Macroaxis provides hands-on modules to deliver winning trades and diversify your portfolios on a daily basis. Most of our advising modules are very easy to use and apply.
Please read more on our stock advisor page.
Use Investing Ideas to Build Portfolios
In addition to having Egetis Therapeutics in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.Did You Try This Idea?
Run Sport Products Thematic Idea Now
Sport Products
Companies manufacturing sporting goods and accessories. The Sport Products theme has 42 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize Sport Products Theme or any other thematic opportunities.
| View All Next | Launch |
Additional Tools for Egetis Stock Analysis
When running Egetis Therapeutics' price analysis, check to measure Egetis Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Egetis Therapeutics is operating at the current time. Most of Egetis Therapeutics' value examination focuses on studying past and present price action to predict the probability of Egetis Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Egetis Therapeutics' price. Additionally, you may evaluate how the addition of Egetis Therapeutics to your portfolios can decrease your overall portfolio volatility.